Literature DB >> 19419607

Pulmonary hypertension associated with congenital diaphragmatic hernia.

Bernard Thébaud1, Dick Tibboel.   

Abstract

Entities:  

Mesh:

Year:  2009        PMID: 19419607     DOI: 10.1017/S1047951109003965

Source DB:  PubMed          Journal:  Cardiol Young        ISSN: 1047-9511            Impact factor:   1.093


× No keyword cloud information.
  5 in total

1.  Antenatal maternally-administered phosphodiesterase type 5 inhibitors normalize eNOS expression in the fetal lamb model of congenital diaphragmatic hernia.

Authors:  Eveline H Shue; Samuel C Schecter; Wenhui Gong; Mozziyar Etemadi; Michael Johengen; Corey Iqbal; S Christopher Derderian; Peter Oishi; Jeffrey R Fineman; Doug Miniati
Journal:  J Pediatr Surg       Date:  2013-10-05       Impact factor: 2.545

2.  High temporal versus high spatial resolution in MR quantitative pulmonary perfusion imaging of two-year old children after congenital diaphragmatic hernia repair.

Authors:  M Weidner; F G Zöllner; C Hagelstein; K Zahn; T Schaible; S O Schoenberg; L R Schad; K W Neff
Journal:  Eur Radiol       Date:  2014-07-20       Impact factor: 5.315

3.  A New Era in Medical Management of Severe Pediatric Pulmonary Arterial Hypertension.

Authors:  Dunbar Ivy; Ben T Saji
Journal:  Nihon Shoni Junkanki Gakkai Zasshi       Date:  2010-06-04

4.  A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011.

Authors:  Maria Jesus Del Cerro; Steven Abman; Gabriel Diaz; Alexandra Heath Freudenthal; Franz Freudenthal; S Harikrishnan; Sheila G Haworth; Dunbar Ivy; Antonio A Lopes; J Usha Raj; Julio Sandoval; Kurt Stenmark; Ian Adatia
Journal:  Pulm Circ       Date:  2011       Impact factor: 3.017

Review 5.  Emerging antenatal therapies for congenital diaphragmatic hernia-induced pulmonary hypertension in preclinical models.

Authors:  Kathleen Marulanda; Nick D Tsihlis; Sean E McLean; Melina R Kibbe
Journal:  Pediatr Res       Date:  2020-10-10       Impact factor: 3.756

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.